CANbridge Pharmaceuticals Inc. (HK:1228) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
CANbridge Pharmaceuticals Inc. reports significant headway in their drug pipeline for rare diseases, with the commercial launch of Hunterase® and Livmarli® in China and the progression of CAN103 through clinical trials. The company has also ventured into gene therapy, licensing a novel technology for Duchenne Muscular Dystrophy treatment, and expects to submit a New Drug Application for CAN103 by the end of 2024.
For further insights into HK:1228 stock, check out TipRanks’ Stock Analysis page.